Trends of concerns from diagnosis in patients with advanced lung cancer and their family caregivers: A 2-year longitudinal study
Takashi Sato(Kitasato University), Kenzo Soejima(Keio University), Takashi Inoue(Japan Atomic Energy Agency), Yoshitaka Oyamada(Keio University), Yasunori Sato(Keio University), Shigenari Nukaga(Tokyo Medical Center), Fumitake Saito(Eiju General Hospital), Keigo Kobayashi(Osaka Gakuin University), Shinnosuke Ikemura(Keio University), Fumio Sakamaki(Keio University), Hideki Terai(Kitasato Institute Hospital), Saeko Takahashi(Saiseikai Central Hospital), Ichiro Nakachi(Saiseikai Utsunomiya hospital), Daisuke Fujisawa(Keio University), Morio Nakamura(Saiseikai Central Hospital), Daisuke Arai(Keio University), Koichi Fukunaga(Keio University), Hiroyuki Yasuda(Beth Israel Deaconess Medical Center), Ichiro Kawada(Keio University), Mizuha Hashiguchi(Nippon Koei (Japan)), Katsuhiko Naoki(Broad Institute), Koichi Sayama(Beth Israel Deaconess Medical Center), Takeshi Terashima(Keio University), Mari Takeuchi(Keio University), Ryosuke Satomi(Tokyo Medical Center)
Cited by 14
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Plasma Brain Natriuretic Peptide as a Prognostic Indicator in Patients With Primary Pulmonary Hypertension
|Circulation|2000|880
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
|The Lancet Oncology|2019|642
Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer
|Science Translational Medicine|2013|565